30 likes | 199 Views
Topic 3: ACPS Questions Highly Variable Drugs. FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS). Topic 3 Question 1: . Does the committee agree with the use of a point estimate constraint when applying scaled bioequivalence? If yes, is the 80 –
E N D
Topic 3: ACPS Questions Highly Variable Drugs FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)
Topic 3 Question 1: Does the committee agree with the use of a point estimate constraint when applying scaled bioequivalence? If yes, is the 80 – 125% limit on the point estimate appropriate? FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)
We propose a minimum sample size of 36 subjects when evaluating the BE of highly variable drugs. Does the Committee concur? Topic 3 Question 2: FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)